AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38991714
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 0.2% + 5 µg/mL epinephrine
Trial: 38992025
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of protein levels and rs6770663
Trial: 38992490
Drug: BEC change
RxNorm normalized name: racepinephrine
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEC change during ICS treatment
Trial: 38993008
Drug: Soticlestat (TAK-935)
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat (TAK-935) 300 mg single oral dose
Trial: 38993026
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg single oral dose in patients with mild hepatic impairment
Trial: 38993026
Drug: Avacopan 30
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avacopan 30 mg single oral dose in patients with moderate hepatic impairment
Trial: 38993150
Drug: SAR442085 (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR442085 (5-7.5 mg/kg)
Trial: 38993983
Drug: Once-weekly HIIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly HIIT (75 min, 16 weeks)
Trial: 38993983
Drug: Thrice-weekly HIIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly HIIT (75 min, 16 weeks)
Trial: 38994348
Drug: MDMA-assisted brief
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA-assisted brief cognitive behavioral conjoint therapy (bCBCT)
Trial: 38994833
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of stool tests with alarm features
Trial: 38995311
Drug: Vimseltinib, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vimseltinib, 30 mg twice weekly
Trial: 38995504
Drug: 1.5% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% ruxolitinib cream (continuous-use)
Trial: 38995504
Drug: 1.5% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% ruxolitinib cream (as-needed use)
Trial: 39420169
Drug: TAK-003 (live-attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-003 (live-attenuated tetravalent dengue vaccine)
Trial: 38996463
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose of CAR22
Trial: 38996972
Drug: 1HP (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1HP (daily rifapentine plus isoniazid for 28 days)
Trial: 38996972
Drug: 3HP (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP (weekly rifapentine plus isoniazid for 3 months)
Trial: 38997229
Drug: Clay-based Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clay-based Traditional Medicine (TM) use (34% of participants)
Trial: 38997279
Drug: Gut microbiota-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiota-based machine learning (ML) algorithms for ALD diagnosis
Trial: 38997279
Drug: Gut microbiota-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiota-based machine learning (ML) algorithms for MASLD diagnosis
Trial: 38997279
Drug: Gut microbiota-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiota-based machine learning (ML) algorithms for ALD and MASLD external validation
Trial: 38997607
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) therapy
Trial: 38997684
Drug: Personalized visualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized visualized oral health education combined with conventional oral hygiene education
Trial: 38997684
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral hygiene education only
Trial: 39001374
Drug: Alpha DaRT
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha DaRT treatment
Trial: 39001413
Drug: Clinical and
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical and biological samples collection
Trial: 39001621
Drug: Bismuth-metronidazole-tetracycline and
RxNorm normalized name: bismuth subcitrate, tetracycline and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-metronidazole-tetracycline and clarithromycin-amoxicillin-bismuth quadruple therapies
Trial: 39001621
Drug: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant clarithromycin-amoxicillin-tinidazole/metronidazole
Trial: 39001621
Drug: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential clarithromycin-amoxicillin-tinidazole/metronidazole
Trial: 39001621
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effectiveness by indication
Trial: 39001864
Drug: Jewel patch
RxNorm normalized name: jewel weed whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jewel patch wearable cardioverter-defibrillator (P-WCD) delivering a single shock of 150 J
Trial: 39002122
Drug: TCK-276 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCK-276 25 mg/day
Trial: 39002122
Drug: TCK-276 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCK-276 75 mg/day
Trial: 39002122
Drug: TCK-276 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCK-276 175 mg/day
Trial: 39002551
Drug: Ruxolitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10 mg twice daily for ages 12-18, 5 mg twice daily for ages 6-12, 4 mg/m² for ages 2-6)
Trial: 39002641
Drug: Pemvidutide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemvidutide treatment
Trial: 39003182
Drug: Trifluridine/tipiracil administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil administered concomitantly to radiotherapy
Trial: 39003185
Drug: Neoadjuvant durvalumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant durvalumab plus platinum-based chemotherapy (D+CT) followed by adjuvant durvalumab
Trial: 39003306
Drug: Somatic mutations
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatic mutations (e.g., TP53, CDH1, PTEN)
Trial: 39004096
Drug: H3N2 M2SR
RxNorm normalized name: Haemagglutinin-strain A(H3N2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2 M2SR vaccine plus Fluzone HD (n=94)
Trial: 39004096
Drug: H3N2 M2SR
RxNorm normalized name: Haemagglutinin-strain A(H3N2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3N2 M2SR vaccine plus placebo (n=89)
Trial: 39004217
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion for 48 hours to maintain HR at 60 to 90 beats/min
Trial: 39004432
Drug: ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ixekizumab (IXE) 80 mg every 4 weeks
Trial: 39004434
Drug: BCG-Denmark vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-Denmark vaccine (0.05 mL intradermal dose)
Trial: 39004647
Drug: SHR-A1811 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 at 4.8 mg/kg
Trial: 39004647
Drug: SHR-A1811 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 at 8.0 mg/kg
Trial: 39004647
Drug: SHR-A1811 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 at 6.4 mg/kg
Trial: 39004848
Drug: Chronic drug
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic drug abuse
Trial: 39005691
Drug: Debulking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debulking therapy (including rituximab-containing immunochemotherapy regimens and radiotherapy)
Trial: 39005691
Drug: Axi-cel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axi-cel treatment
Trial: 39006315
Drug: RBL (REBYOTA®)
RxNorm normalized name: Rebyota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBL (REBYOTA®) administration after non-CDI antibiotic use
Trial: 39006315
Drug: High-risk antibiotics
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk antibiotics
Trial: 39006430
Drug: Fluorometholone 0.1%
RxNorm normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone 0.1% eyedrops twice daily for four weeks
Trial: 39007062
Drug: Mogamulizumab treatment
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mogamulizumab treatment
Trial: 39007065
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m² combined with cyclophosphamide and vincristine (VPC)
Trial: 39007065
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) at a dose of 30 mg/m²
Trial: 39007556
Drug: Emergency mechanical
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency mechanical reperfusion (EMR) treatment
Trial: 39007703
Drug: Trauma-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive Behavioral Therapy combined with Cognitive-Behavioral Therapy for eating disorders (TF-CBT-WB)
Trial: 39007830
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor)
Trial: 39007942
Drug: Low IFN-γ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low IFN-γ, TNF and IL-1β before treatment (Arm 2)
Trial: 39007942
Drug: Arm 1
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 treatment in patients with low IFN-γ production at D0
Trial: 39008067
Drug: Rechallenge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenge of RLT (Radioligand Therapy)
Trial: 39008236
Drug: Tirzepatide (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (pooled doses of 5, 10, and 15 mg)
Trial: 39008481
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) and WT1/DC vaccination (8-10 x 106 cells/vaccination) in combination with standard-of-care chemotherapy (cisplatinum 75mg/m2 and pemetrexed 500mg/m2)
Trial: 39008542
Drug: Cladribine (CLAD)
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine (CLAD) tablets
Trial: 39008999
Drug: Emtricitabine plus
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine plus tenofovir alafenamide (200/300 mg)
Trial: 39008999
Drug: Emtricitabine plus
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine plus tenofovir disoproxil fumarate (200/25 mg)
Trial: 39009085
Drug: Bulevirtide 2
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 2 mg/day
Trial: 39009085
Drug: Bulevirtide 10
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 10 mg/day
Trial: 39009116
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein > 2 mg/l
Trial: 39009116
Drug: Low high-density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low high-density lipoprotein levels (<1200 mmol/l)
Trial: 39009312
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (up to a 21 mg daily dose over 12 weeks)
Trial: 39009356
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil concentrate (KOC) 4 g/day for 24 weeks
Trial: 39009368
Drug: Opioid prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid prescriptions at emergency department discharge
Trial: 39009368
Drug: Smaller, cause-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smaller, cause-specific opioid prescriptions
Trial: 39009709
Drug: Nilotinib (Tasigna)
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib (Tasigna) treatment for 1 year
Trial: 39010171
Drug: Dexmedetomidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine nasal spray 0.2 µg/kg
Trial: 39010171
Drug: Dexmedetomidine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine nasal spray 0.5 µg/kg
Trial: 39010748
Drug: Training to
RxNorm normalized name: Poloxamer 407/Simethicone 2%-0.12% Dental Paste [ORAJEL TODDLER TRAINING TOOTHPASTE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training to deal with distractions and conflicting situations in activities of daily living after TBI
Trial: 39192339
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial plus RB-PDT
Trial: 39192339
Drug: Topical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antimicrobial plus sham RB-PDT
Trial: 39012226
Drug: Pyrazinamide treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide treatment, dosage and duration not specified
Trial: 39012717
Drug: Setrusumab 20
RxNorm normalized name: Setrusumab
DrugBank: Setrusumab (DB14778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setrusumab 20 mg/kg
Trial: 39012717
Drug: Setrusumab 8
RxNorm normalized name: Setrusumab
DrugBank: Setrusumab (DB14778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setrusumab 8 mg/kg
Trial: 39012930
Drug: Personalized prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized prescription of pacing (PPoP) for 6 months
Trial: 39012946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperglycemia with low HDL cholesterol
Trial: 39012946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperglycemia with high systemic blood pressure
Trial: 39013470
Drug: Allogeneic CD19-targeted
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic CD19-targeted CAR-T therapy
Trial: 39013886
Drug: NeoAdjuvant ChemoTherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoAdjuvant ChemoTherapy (NACT) + Pembrolizumab (P)
Trial: 39013886
Drug: NeoAdjuvant ChemoTherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeoAdjuvant ChemoTherapy (NACT)
Trial: 39014136
Drug: CRP quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP quartile Q1 (<8 mg/L)
Trial: 39014136
Drug: CRP quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP quartile Q2 (8-28 mg/L)
Trial: 39014136
Drug: CRP quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP quartile Q3 (>28-69 mg/L)
Trial: 39014136
Drug: CRP quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP quartile Q4 (>69 mg/L)
Trial: 39014448
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay)
Trial: 39014498
Drug: Narrowband UVB
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Narrowband UVB (NB-UVB) combined with optimal topical therapy (OTT) for a minimum of 3 months and 8 to 16 weeks of NB-UVB
Trial: 39014498
Drug: Optimal topical
RxNorm normalized name: Optima Plus Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal topical therapy (OTT) for 3 months
Trial: 39014980
Drug: Primary control
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary control engagement coping (e.g., problem-solving)
Trial: 39014980
Drug: Secondary control
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary control engagement coping (e.g., positive thinking)
Trial: 39015065
Drug: Caregiver Global
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caregiver Global Impression of Change in memory or daily activities
Trial: 39015674
Drug: Autologous Bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Bone Marrow-Derived Mononuclear Cell Infusion into Renal Arteries
Trial: 39016024
Drug: Topical Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cannabidiol
Trial: 39016381
Drug: Multimodal enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal enhanced recovery pathway including preoperative and postoperative nonopioid analgesia with oral acetaminophen, gabapentin, and ketorolac.
Trial: 39016593
Drug: Molecular dihydrogen
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular dihydrogen (H2) inhalation therapy (3.6% H2 and 96.4% N2)
Trial: 39016594
Drug: Linezolid (LZD)
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid (LZD) treatment over 14 days
Trial: 39017661
Drug: Oral microbiome
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiome in patients with oral cGVHD
Trial: 39017661
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and gut microbiota overlap
Trial: 39017661
Drug: Longitudinal trajectories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal trajectories of oral and gut microbiomes
Trial: 39018038
Drug: Cendakimab 720
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendakimab 720 mg, once weekly
Trial: 39018038
Drug: Cendakimab 720
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendakimab 720 mg, every 2 weeks
Trial: 39018038
Drug: Cendakimab 360
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendakimab 360 mg, every 2 weeks
Trial: 39018071
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (support for lactation, kangaroo care, and routine developmental therapies)
Trial: 39018444
Drug: Quantifiable spike
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantifiable spike antibody (Ab)
Trial: 39018444
Drug: Unquantifiable spike
RxNorm normalized name: spike lavender oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unquantifiable spike antibody (Ab)
Trial: 39018532
Drug: 5-day nirmatrelvir-ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 5 days)
Trial: 39018532
Drug: 10-day nirmatrelvir-ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day nirmatrelvir-ritonavir (300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for 10 days)
Trial: 39018898
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) pregabalin (150 mg once daily)
Trial: 39018898
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) pregabalin (75 mg twice daily)
Trial: 39019119
Drug: Low BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low BC (392 mg/day)
Trial: 39019119
Drug: High BC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High BC (784 mg/day)
Trial: 39019203
Drug: Stellarex Drug-Coated
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellarex Drug-Coated Balloon (2 µg/mm)
Trial: 39019639
Drug: Implant-based breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-based breast reconstruction
Trial: 39019657
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of mRNA-1273